Drug Trial Radar · NCT05805501
A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
199
Actual
Start
Apr 21, 2023
Primary completion
Oct 5, 2026
Study completion Oct 5, 2026
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Apr 10, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the safety of tobemstomig (RO7247669) in combination with axitinib alone or with tiragolumab (anti-TIGIT) and axitinib as compared to pembrolizumab and axitinib in participants with previously untreated, unresectable locally advanced or metastatic clear-cell renal cell carcinoma (ccRCC).
Conditions
- Renal Cell Carcinoma
Interventions
TobemstomigDrug
Participants will receive IV tobemstomig Q3W.
TiragolumabDrug
Participants will receive IV tiragolumab Q3W.
PembrolizumabDrug
Participants will receive IV pembrolizumab Q3W.
AxitinibDrug
Participants will receive axitinib PO BID.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and Severity of Adverse Events (AEs)Time frame: Up to a maximum of 2 years
Locations
42 sites in 9 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
UC Irvine Medical Center
Orange, California
Emory University
Atlanta, Georgia
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland
SCRI Oncology Partners
Nashville, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee
UT Southwestern Medical Center
Dallas, Texas
Sunshine Coast University Hospital
Birtinya, Queensland, Australia
Beijing Cancer Hospital
Beijing, China
Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School
Nanjing, China
Tianjin Cancer Hospital
Tianjin, China
Institut Sainte Catherine
Avignon, France
CHU Besançon - Hôpital Jean Minjoz
Besançon, France
CHU de Bordeaux - Groupe Hospitalier Saint-André - Hopital Saint-Andre
Bordeaux, France
Centre Francois Baclesse
Caen, France
Centre Leon Berard
Lyon, France
Institut Gustave Roussy
Villejuif, France
Universitätsklinikum "Carl Gustav Carus"
Dresden, Germany
Universitätsklinikum Hamburg-Eppendorf Onkologisches Zentrum Medizinische Klinik II
Hamburg, Germany
Medizinische Hochschule Hannover
Hanover, Germany
Klinikum rechts der Isar der TU München
München, Germany
Studienpraxis Urologie
Nürtingen, Germany
Universitätsklinikum Ulm
Ulm, Germany
Szpital Specjalistyczny Podkarpacki O?rodek Onkologiczny
Brzozów, Poland
Centrum Onkologii im. Prof. Franciszka ?ukaszczyka
Bydgoszcz, Poland
Szpital Uniwersytecki w Krakowie, Oddzia? Kliniczny Kliniki Onkologii
Krakow, Poland
Szpital Kliniczny im. Heliodora ?wi?cickiego UM w Poznaniu
Późna, Poland
National Cancer Center
Goyang-si, South Korea
Chonnam National University Hwasun Hospital
Jeollanam-do, South Korea
Severance Hospital, Yonsei University Health System
Seoul, South Korea
Asan Medical Center
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Hospital de la Santa Creu i Sant Pau
Barcelona, Spain
Hospital Universitari Vall d'Hebron
Barcelona, Spain
Hospital Universitario Ramon y Cajal
Madrid, Spain
Hospital Universitario Clínico San Carlos
Madrid, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
Hospital Universitario Virgen del Rocio
Seville, Spain
Hospital Universitari i Politecnic La Fe
Valencia, Spain
Hospital Universitario Reina Sofia
Córdoba, Cordoba, Spain
Showing 40 of 42 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.